Literature DB >> 24922669

XRCC1 rs25487 polymorphism predicts the survival of patients after postoperative radiotherapy and adjuvant chemotherapy for breast cancer.

Maria Tengström1, Arto Mannermaa2, Veli-Matti Kosma2, Ari Hirvonen3, Vesa Kataja4.   

Abstract

BACKGROUND: Single nucleotide polymorphisms (SNPs) in a DNA-repair gene, X-Ray repair cross complementing group 1 (XRCC1), have been associated with the survival of patients with breast cancer. We investigated the predictive value of XRCC1 SNP (rs25487) in patients with early breast cancer. PATIENTS AND METHODS: The XRCC1 rs25487 genotypes of 411 Finnish patients with breast cancer were analyzed by a polymerase chain reaction-restriction fragment length polymorphism-based method. Survival was assessed by Kaplan-Meier method and Cox regression analysis according to the XRCC1 genotypes in specified adjuvant treatment groups.
RESULTS: The rs25487 variant AA genotype was associated with worse breast cancer-specific and overall survival in 238 patients receiving postoperative radiotherapy (p=0.031 and p=0.030, respectively). The AA genotype predicted worse breast cancer-specific survival among 75 patients treated with adjuvant chemotherapy (p=0.047).
CONCLUSION: The XRCC1 rs25487 genotype may predict the outcome of postoperative radiotherapy and adjuvant chemotherapy in breast cancer. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  XRCC1; breast cancer; chemotherapy; polymorphism; radiotherapy

Mesh:

Substances:

Year:  2014        PMID: 24922669

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  XRCC1 polymorphisms associated with survival among Chinese bladder cancer patients receiving epirubicin and mitomycin C.

Authors:  Xiaheng Deng; Xiaolei Zhang; Yidong Cheng; Xiao Yang; Ruizhe Zhao; Xuzhong Liu; Xiao Li; Chao Qin; Qiang Lu; Changjun Yin
Journal:  Tumour Biol       Date:  2015-01-25

2.  Identifying Circulating Tumor DNA Mutations Associated with Neoadjuvant Chemotherapy Efficacy in Local Advanced Breast Cancer.

Authors:  Benjie Wei; Yanhong Shan; Haifeng Lin; Zhaoli Du; Chunxia Yin; Qianqian Zhang; Guirong Zhang; Dong Song; Hongbin Zuo
Journal:  Appl Biochem Biotechnol       Date:  2022-09       Impact factor: 3.094

3.  Association of XRCC1 Trp194 allele with risk of breast cancer, and Ki67 protein status in breast tumor tissues.

Authors:  Chiya Jalali; Bayazid Ghaderi; Sabrieh Amini; Mohammad Abdi; Daem Roshani
Journal:  Saudi Med J       Date:  2016-06       Impact factor: 1.484

4.  Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.

Authors:  Karolina Tecza; Jolanta Pamula-Pilat; Joanna Lanuszewska; Dorota Butkiewicz; Ewa Grzybowska
Journal:  Oncotarget       Date:  2018-01-10

5.  XRCC1 rs1799782 (C194T) polymorphism correlated with tumor metastasis and molecular subtypes in breast cancer.

Authors:  Qing Li; Rong Ma; Mei Zhang
Journal:  Onco Targets Ther       Date:  2018-11-28       Impact factor: 4.147

6.  A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.

Authors:  Petra Seibold; Peter Schmezer; Sabine Behrens; Kyriaki Michailidou; Manjeet K Bolla; Qin Wang; Dieter Flesch-Janys; Heli Nevanlinna; Rainer Fagerholm; Kristiina Aittomäki; Carl Blomqvist; Sara Margolin; Arto Mannermaa; Vesa Kataja; Veli-Matti Kosma; Jaana M Hartikainen; Diether Lambrechts; Hans Wildiers; Vessela Kristensen; Grethe Grenaker Alnæs; Silje Nord; Anne-Lise Borresen-Dale; Maartje J Hooning; Antoinette Hollestelle; Agnes Jager; Caroline Seynaeve; Jingmei Li; Jianjun Liu; Keith Humphreys; Alison M Dunning; Valerie Rhenius; Mitul Shah; Maria Kabisch; Diana Torres; Hans-Ulrich Ulmer; Ute Hamann; Joellen M Schildkraut; Kristen S Purrington; Fergus J Couch; Per Hall; Paul Pharoah; Doug F Easton; Marjanka K Schmidt; Jenny Chang-Claude; Odilia Popanda
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

7.  X-ray repair cross-complementing protein 1 and 3 polymorphisms and susceptibility of breast cancer in a Jordanian population.

Authors:  Mazhar S Al Zoubi
Journal:  Saudi Med J       Date:  2015-10       Impact factor: 1.484

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.